$COSMJun 18, 2026, 7:34 PMAI processed
COSM subsidiary CosmoFarm reports Q2 revenue >$15M, $60M+ annualized run-rate; adds 80+ pharmacies and expands automation
AI Summary
CosmoFarm, the wholly owned Cosmos Health (COSM) subsidiary, reported record Q2 2026 revenue of over $15M, implying an annualized run-rate above $60M, and added more than 80 pharmacies to its distribution network. The company says it is increasing capex for robotic automation, AI-driven procurement/inventory systems and facility expansion to support higher volumes and improve unit economics.
Positives
- CosmoFarm reported record Q2 revenue >$15M, implying >$60M annualized run-rate
- Added 80+ new pharmacies during the quarter, expanding distribution footprint
- Announced capex to add robotic automation and AI systems and expand facility capacity to support scaling
Negatives
- Release gives no consolidated COSM GAAP figures or profitability metrics
- Reported figure is for the CosmoFarm subsidiary specifically, not necessarily company-wide results
- Forward-looking investments and growth subject to financing, operational and geopolitical risks per company disclaimer